share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/08/30 11:41

Moomoo AI 已提取核心信息

Ensysce Biosciences has entered into definitive agreements to raise $5M through a registered direct offering and warrant exercise. The company will issue 3,553,194 shares at $0.47 per share and allow exercise of existing warrants for 7,203,504 shares at a reduced price of $0.47, down from $1.06.In a concurrent private placement, the company will issue Series A-3 and A-4 unregistered warrants to purchase up to 28.7M shares at $0.47 per share, exercisable upon stockholder approval. The Series A-3 warrants have an 18-month term while Series A-4 warrants extend for 5 years.The proceeds will support development of TAAP and MPAR programs, complementing a recent $14M NIH grant for PF614-MPAR development. H.C. Wainwright & Co. serves as exclusive placement agent, with closing expected around August 29, 2024.
Ensysce Biosciences has entered into definitive agreements to raise $5M through a registered direct offering and warrant exercise. The company will issue 3,553,194 shares at $0.47 per share and allow exercise of existing warrants for 7,203,504 shares at a reduced price of $0.47, down from $1.06.In a concurrent private placement, the company will issue Series A-3 and A-4 unregistered warrants to purchase up to 28.7M shares at $0.47 per share, exercisable upon stockholder approval. The Series A-3 warrants have an 18-month term while Series A-4 warrants extend for 5 years.The proceeds will support development of TAAP and MPAR programs, complementing a recent $14M NIH grant for PF614-MPAR development. H.C. Wainwright & Co. serves as exclusive placement agent, with closing expected around August 29, 2024.
Ensysce Biosciences已签署最终协议,通过注册直接发行和Warrants行使筹集500万美元。该公司将以每股0.47美元的价格发行3,553,194股股票,并允许以0.47美元的降低价格行使现有Warrants,原价格为1.06美元。在同时进行的定向增发中,该公司将发行未注册的A-3和A-4系列Warrants,允许以每股0.47美元的价格购买最多2870万股,需经股东批准后行使。A-3系列Warrants的有效期为18个月,而A-4系列Warrants的有效期为5年。这笔资金将支持TAAP和MPAR项目的发展,补充最近获得的1400万美元的NIH资助,用于PF614-MPAR的发展。H.C. Wainwright & Co.担任独家 placement agent,预计将在2024年8月29日左右完成交易。
Ensysce Biosciences已签署最终协议,通过注册直接发行和Warrants行使筹集500万美元。该公司将以每股0.47美元的价格发行3,553,194股股票,并允许以0.47美元的降低价格行使现有Warrants,原价格为1.06美元。在同时进行的定向增发中,该公司将发行未注册的A-3和A-4系列Warrants,允许以每股0.47美元的价格购买最多2870万股,需经股东批准后行使。A-3系列Warrants的有效期为18个月,而A-4系列Warrants的有效期为5年。这笔资金将支持TAAP和MPAR项目的发展,补充最近获得的1400万美元的NIH资助,用于PF614-MPAR的发展。H.C. Wainwright & Co.担任独家 placement agent,预计将在2024年8月29日左右完成交易。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息